304 related articles for article (PubMed ID: 25613729)
1. EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management.
Ok CY; Li L; Young KH
Exp Mol Med; 2015 Jan; 47(1):e132. PubMed ID: 25613729
[TBL] [Abstract][Full Text] [Related]
2. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
Kalla M; Hammerschmidt W
Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders.
Cai Q; Chen K; Young KH
Exp Mol Med; 2015 Jan; 47(1):e133. PubMed ID: 25613730
[TBL] [Abstract][Full Text] [Related]
4. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target.
Tse E; Kwong YL
Exp Mol Med; 2015 Jan; 47(1):e136. PubMed ID: 25613733
[TBL] [Abstract][Full Text] [Related]
5. Latent membrane protein 1 of Epstein-Barr virus plays an important role in the serum starvation resistance of Epstein-Barr virus-immortalized B lymphocytes.
Park CH; Kim HR; Kim J; Jang SH; Lee KY; Chung GH; Jang YS
J Cell Biochem; 2004 Mar; 91(4):777-85. PubMed ID: 14991769
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.
Rea D; Fourcade C; Leblond V; Rowe M; Joab I; Edelman L; Bitker MO; Gandjbakhch I; Suberbielle C; Farcet JP
Transplantation; 1994 Aug; 58(3):317-24. PubMed ID: 8053055
[TBL] [Abstract][Full Text] [Related]
7. Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
Bilger A; Plowshay J; Ma S; Nawandar D; Barlow EA; Romero-Masters JC; Bristol JA; Li Z; Tsai MH; Delecluse HJ; Kenney SC
Oncotarget; 2017 Jul; 8(27):44266-44280. PubMed ID: 28574826
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of Epstein-Barr virus in B cells of patients with chronic hepatitis C.
Shimozuma Y; Ito T; Inokuchi M; Uchikoshi M; Miyashita M; Nozawa H; Shimazaki T; Hiroishi K; Imawari M
J Med Virol; 2010 Dec; 82(12):2064-72. PubMed ID: 20981794
[TBL] [Abstract][Full Text] [Related]
9. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
Dolcetti R
Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders.
Ghigna MR; Reineke T; Rincé P; Schüffler P; El Mchichi B; Fabre M; Jacquemin E; Durrbach A; Samuel D; Joab I; Guettier C; Lucioni M; Paulli M; Tinguely M; Raphael M
Pathobiology; 2013; 80(2):53-9. PubMed ID: 22868923
[TBL] [Abstract][Full Text] [Related]
11. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway.
Portis T; Longnecker R
Oncogene; 2004 Nov; 23(53):8619-28. PubMed ID: 15361852
[TBL] [Abstract][Full Text] [Related]
13. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells.
Rasul AE; Nagy N; Sohlberg E; Ádori M; Claesson HE; Klein G; Klein E
J Immunol Methods; 2012 Nov; 385(1-2):60-70. PubMed ID: 22921685
[TBL] [Abstract][Full Text] [Related]
15. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.
Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D
Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation.
Chuhjo T; Yachie A; Kanegane H; Kimura H; Shiobara S; Nakao S
Am J Hematol; 2003 Apr; 72(4):255-8. PubMed ID: 12666136
[TBL] [Abstract][Full Text] [Related]
17. Plasmacytic hyperplasia in age-related Epstein-Barr virus-associated lymphoproliferative disorders: a report of two cases.
Kojima M; Morita Y; Nakamura N; Shimizu K; Murayama K; Nakamura S
Pathol Res Pract; 2008; 204(4):267-72. PubMed ID: 18187262
[TBL] [Abstract][Full Text] [Related]
18. hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis.
Terrin L; Dolcetti R; Corradini I; Indraccolo S; Dal Col J; Bertorelle R; Bonaldi L; Esposito G; De Rossi A
Int J Cancer; 2007 Aug; 121(3):576-87. PubMed ID: 17417773
[TBL] [Abstract][Full Text] [Related]
19. Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments.
Neparidze N; Lacy J
Clin Adv Hematol Oncol; 2014 Jun; 12(6):358-71. PubMed ID: 25003566
[TBL] [Abstract][Full Text] [Related]
20. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
Johnson LR; Nalesnik MA; Swerdlow SH
Am J Surg Pathol; 2006 Dec; 30(12):1604-12. PubMed ID: 17122518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
